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Edited by Veli-Pekka LehtoAbstract Histone deacetylase inhibitors (HDACi) have been
discovered as potential drugs for cancer treatment. The eﬀect
of BL1521, a novel HDACi, on the cell cycle distribution and
the induction of apoptosis was investigated in a panel ofMYCN
single copy and MYCN ampliﬁed neuroblastoma cell lines.
BL1521 arrested neuroblastoma cells in the G1 phase and in-
duced up to 30% apoptosis. Downregulation of CDK4, upregula-
tion of p21WAF1/CIP1 and an increase of hypophosphorylated
retinoblastoma protein were observed, indicating a possible
mechanism for the cell-cycle arrest. BL1521 also induced down-
regulation of p27, which may underlie the observed induction of
apoptosis.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Neuroblastoma is a common childhood tumor originating
from neural crest cells in the sympathetic nervous system
and is responsible for over 15% of cancer-related death in chil-
dren [1,2]. The clinical diversity of neuroblastoma correlates
with several characteristic genetic features [1]. One of the best
genetic markers of poor prognosis is the ampliﬁcation of the
MYCN gene. These tumors do not respond as well to the treat-
ment used in the clinic today as compared to those without
MYCN ampliﬁcation, consequently leading to a disease related
mortality of up to 70% [1,3]. Therefore, the development of
new therapeutic strategies is warranted.
Histone deacetylase (HDAC) has recently been discovered
as a potential target for the development of new therapeuticAbbreviations: HDAC, histone deacetylase; HDACi, histone deacetyl-
ase inhibitor; TSA, trichostatin A; CDK, cyclin dependent kinase; RT,
room temperature; HRP, horseradish peroxidase; Rb; retinoblastoma
protein
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doi:10.1016/j.febslet.2005.01.058agents [4]. Deacetylation of histones results in a tightened
chromatin structure and reduces the accessibility of DNA,
leading to a decrease in transcriptional activity [5,6]. When
HDAC function is inhibited, histones remain acetylated,
resulting in a more open chromatin conformation, which facil-
itates the transcription of genes [6]. It has been shown that in a
variety of tumor cells, these changes resulted in a reduction of
proliferation and metabolic activity and in an induction of
apoptosis and diﬀerentiation, both in vitro and in vivo [4].
Thus far, a number of histone deacetylase inhibitor (HDA-
Ci) have been identiﬁed with diﬀerent anti-tumor activity,
speciﬁcity, toxicity, and stability [4,6]. To date, conﬂicting re-
sults exists as to the eﬀect of HDACi on cell cycle distribution.
In a majority of tumor cells, HDACi appeared to upregulate
the expression of p21WAF1/CIP1 and downregulate cyclin D1,
which was paralleled by a cell cycle arrest in G1 phase. How-
ever, downregulation of cyclin B1 together with a G2/M arrest
has also been observed in response to HDACi treatment in tu-
mor cells [7,8].
Treatment of neuroblastoma cells with a recently developed
HDACi, BL1521 resulted in a signiﬁcant decrease in cell pro-
liferation, metabolic activity, and MYCN expression [9]. To
date, the underlying mechanism for these observed eﬀects is
not known. Therefore, we have investigated the eﬀect of
BL1521 on the cell cycle distribution and the expression of cell
cycle regulating proteins in a panel of neuroblastoma cell lines
with diﬀerent MYCN status.2. Materials and methods
2.1. Cell culture
Three MYCN single copy neuroblastoma cell lines, SKNAS,
SKNSH, and GIMEN, and three MYCN ampliﬁed neuroblastoma
cell lines, SJNB8, SKNBE(2), and IMR32, were cultured in RPMI
1640 supplemented with 10% (v/v) heat inactivated fetal bovine ser-
um, 50 U/ml penicillin/streptomycin, 0.2 mg/ml gentamycin, 0.25 lg/
ml fungizone, and 4 mM glutamine. Cells were cultured at 37 C
in a 90% humidiﬁed atmosphere under 6.0% CO2. All incubations
of cells with compounds were carried out by preparing a 1:1000 dilu-
tion from the DMSO stock solutions in culture medium directly be-
fore use.
2.2. Flowcytometry
The percentage of cells in G1, S, and G2-M phase of the cell cycle
was determined by ﬂowcytometry using a bromodeoxyuridine (BrdU)
and propidium iodide (PI) DNA staining procedure [10]. The stainedation of European Biochemical Societies.
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Fig. 1. Eﬀects of BL1521 on the number of viable neuroblastoma cells.
Growth curve analysis of MYCN single copy (GIMEN) and MYCN
ampliﬁed (SKNBE(2)) cells was determined by counting the cells
following treatment with either 6 or 12 lMBL1521. Data represent the
average of four independent experiments and includes standard
deviations.
Fig. 2. Univariate analysis of cell cycle distribution of neuroblastoma cells w
The number of cells is plotted against PI-ﬂuorescence as a measure of DNA
cycle are depicted and the sub-G1 region, which is indicative of apoptosis
Representative examples are shown of three separate experiments.
1524 K. Ouwehand et al. / FEBS Letters 579 (2005) 1523–1528cell nuclei were run on a FACS calibur (Beckton–Dickinson) ﬂowcy-
tometer and the data were subsequently analyzed using the WinMD1
version 2.7 software.
2.3. Staining of apoptotic cells with bis-benzimide (Hoechst, 33342)
The nuclear fragmentation of apoptotic cells was assessed by stain-
ing the cells with the DNA ﬂuorochrome bis-benzimide (Hoechst,
33342). Cells were grown in polystyrene slide ﬂasks. After treatment
of the cells with BL1521, they were ﬁxed by adding 3 ml of a 1:3 meth-
anol–acetic acid solution to the medium (3 ml) and incubated for 5 min
at room temperature (RT), followed by replacing the mixture with
pure 1:3 methanol–acetic acid twice. The ﬁxed cells were air dried
and incubated with 10 mg/ml bis-benzimide (Sigma) in PBS at RT
for 20 min. Subsequently, the cells were washed three times in MilliQ
after which the cells were examined using a ﬂuorescence microscope
(Zeiss), ﬁlter 395–440, FT 460, LP 470. Cells with condensed chroma-
tin or fragmented nuclei were considered to be apoptotic.2.4. Trypan blue dye exclusion test
The loss of membrane integrity in dying cells allows the preferential
uptake of trypan blue. Cells were harvested using 1· trypsin–EDTA
(Sigma) in PBS. Thereafter, 10 ll of the suspended cells was mixed
with 10 ll of 0.4% (w/v) trypan blue in PBS, and examined using a
Bu¨rkerturk counting frame.ith or without ampliﬁed MYCN, treated with 6 lM BL1521 for 24 h.
content. In the top left ﬁgure, the G1, S, and G2/M phases of the cell
. TSA was included as a positive control for G1 arrest by HDACi.
K. Ouwehand et al. / FEBS Letters 579 (2005) 1523–1528 15252.5. Western analysis
Expression levels of proteins were determined by western analysis,
according to the methods used in Ref. [9]. Rabbit polyclonal anti-
bodies against CDK4 (Santa Cruz) and p27 (AbCam) were used in
combination with swine-anti-rabbit polyclonal antibody, conjugated
to horseradish peroxidase (HRP) (Dako Cytomation). Mouse mono-
clonal antibodies against p21WAF1/CIP1 and retinoblastoma protein
(Rb, BD Pharming Gen) were used in combination with rabbit-
anti-mouse polyclonal antibodies, conjugated to HRP (Biorad for
p21waf1/cip1 detection and Dako Cytomation for Rb detection). The
signal was detected with ECL+ (Amersham Bioscience) and Bio-
Max light ﬁlm (Kodak). Equal loading of the gels was determined
using Ponceau staining.Fig. 3. Bivariate ﬂowcytometry with MYCN single copy (SKNAS)
and MYCN ampliﬁed (IMR32) neuroblastoma cells, treated with
BL1521 compared to control. Representative results of four indepen-
dent experiments are shown, with a SD ± 8. Similar results were found
in other single copy and ampliﬁed MYCN cell lines.
Fig. 4. Western blot analysis of p21WAF1/CIP1, CDK4, Rb, and p27
protein. Cells were incubated for 24 h with either 6 or 12 lM BL1521.
Results were shown for neuroblastoma cells with ampliﬁed MYCN
status (SJNB8) and single copy MYCN status (GIMEN).3. Results
To quantify the anti-proliferative eﬀects of BL1521 in neuro-
blastoma cells, the cell panel was cultured with diﬀerent con-
centrations of BL1521 for 1, 2, and 3 days. Representative
examples after BL1521 treatment for MYCN single copy and
MYCN ampliﬁed neuroblastoma cells are shown in Fig. 1. A
signiﬁcant time-dependent decrease in cell number was ob-
served in response to incubation with BL1521, demonstrating
that BL1521 was cytotoxic for the neuroblastoma cells. A
3-day incubation with 12 lM BL1521 resulted in a 92% reduc-
tion of the number of viable GIMEN cells and a 83% reduc-
tion of the number of viable SKNBE(2) cells compared to
the untreated cells.
The eﬀect of BL1521 on the cell cycle of neuroblastoma cells
is shown in Fig. 2. Upon treatment of either single copy or
ampliﬁed MYCN cells with BL1521, the cell cycle distribution
of the cells, was markedly changed. The amount of cells in S
phase as well as the G2/M phase decreased, whereas the
amount of cells in the sub-G1 and G1 phase showed a substan-
tial increase. The cells in the sub-G1 were identiﬁed as dead
cells.
To quantify the amount of S phase cells, BrdU incorpora-
tion studies were performed. After 24 h of BL1521 treatment,
neuroblastoma cells exhibited a marked decrease of the
amount of cells in S phase and G2/M phase paralleled by an
increase of cells in G1 phase. Representative results are shown
in Fig. 3: in response to BL1521 SKNAS and IMR32 cells
showed a reduction of S phase of 22.9% and 43.2%, respec-
tively. Interestingly, part of the S-phase cells did not incorpo-
rate BrdU and these cells were therefore deﬁned as dying or
dead cells according to Ref. [11].
To elucidate the mechanism behind the induction of G1
phase arrest by BL1521, we studied the change in concentra-
tion of the cyclin dependent kinase (CDK) inhibitors
p21WAF1/CIP1 and p27, CDK4, and the change in Rb phos-
phorylation status in neuroblastoma cells (Fig. 4). The amount
of the p21WAF1/CIP1 protein increased in response to treatment
with BL1521 as was expected from our previous studies [9]. In
contrast, the protein concentration of p27 had decreased upon
BL1521 treatment. This decrease of p27 was more substantial
for theMYCN ampliﬁed cell line, compared to theMYCN sin-
gle copy cell line. Furthermore, the complex partner of cyclin
D, CDK4, also showed reduced expression in response to
BL1521 treatment. In line with the increased p21WAF1/CIP1 le-
vel and the decreased CDK4 level, an increase in the hypo-
phosphorylated state of Rb was observed.
To quantify the amount of apoptosis induced by BL1521,
nuclear fragmentation was determined. Fig. 5A shows normalcell nuclei of untreated cells and fragmented cell nuclei after
24 h of treatment with BL1521. The number of cells displaying
these fragmented cell nuclei increased in a dose responsive
fashion as is shown in Fig. 5B. The MYCN ampliﬁed neuro-
blastoma cell line SKNBE(2) showed a signiﬁcant increase
(P < 0.05) in the number of apoptotic cells from 1.9% ± 0.5
for control cells, after treatment with 6 lM BL1521
15.9% ± 8.0 up to 31.8% (±12.8) after treatment with 12 lM
of BL1521. The MYCN single copy cell line, GIMEN, ap-
peared to be less sensitive to the induction of apoptosis by
BL1521, resulting in a maximal induction of apoptosis of
9.7% ± 6.9 after treatment with 12 lM of BL1521.
Fig. 5. (A) The nuclear staining of MYCN single copy neuroblastoma cells (GIMEN) and MYCN ampliﬁed neuroblastoma cells (SKNBE(2)) with
Hoechst. On the left control cells were shown, whereas on the right cells treated with 12 lM BL1521 for 24 h. (B) The percentage of fragmented cell
nuclei of neuroblastoma cells, with (SKNBE(2)) or without (GIMEN) ampliﬁedMYCN status, treated for 24 h with either 6 or 12 lM BL1521. Data
represent the average of three independent experiments and includes standard deviations. *Signiﬁcant diﬀerence compared to control (P < 0.05 using
t test).
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In this study, we investigated the underlying mechanism for
the observed decrease in proliferation found in neuroblastoma
cells in response to incubation with the HDACi BL1521.
Therefore, we determined the eﬀects of BL1521 on the cell cy-
cle and quantiﬁed the amount of apoptosis. Our results
showed that BL1521 induced both an arrest in the G1 phase
of the cell cycle and an increase in the number of apoptotic
cells. Several mechanisms are able to induce the observed G1
arrest, as depicted in Fig. 6. We identiﬁed four diﬀerent possi-
bilities which will be discussed in more detail in the following
sections.
The induction of G1 arrest could be resulting from the
upregulation of the members of the CIP/KIP family of
cyclin–CDK inhibitors p21WAF1/CIP1, p27, and p57.
p21WAF1/CIP1 is able to reduce the progression through the
G1 phase and transition into the S phase in cells through,
on the one hand, activating the restriction-point of the cell
cycle and on the other hand, the inhibition of CDK2 andFig. 6. Regulation of the G1-S transition by the cyclin–Ccyclin D–CDK4/6 complexes [12–15]. Cyclin–CDK complex
activity is necessary for the progression of the cell cycle
through G1-S and G2-M (Fig. 6) [12,14]. When the restric-
tion-point is activated no transition into S phase can take
place and cells become more prone to apoptosis [16].
It has been shown that a number of HDACi are able to in-
crease the expression of p21WAF1/CIP1 [17–20]. We previously
showed that BL1521 treatment of neuroblastoma cells resulted
in an increase of p21WAF1/CIP1 mRNA [9]. This study showed
that the concentration of p21WAF1/CIP1 protein increased as
well. Although it has been reported that in some neuroblas-
toma cell lines the endogenous p21WAF1/CIP1 is dysfunctional,
the upregulation of p21WAF1/CIP1 may still be partly responsi-
ble for the observed G1 phase arrest [21]. Unexpectedly the
concentration of the p27 protein decreased in response to
treatment with BL1521. Recently, it was described that p27
knock out cells were more sensitive to apoptotic stimuli than
wild-type p27 cells and that a high concentration of p27 in
the cytoplasm favor the survival under conditions, which nor-
mally induce apoptosis [22,23]. Since we observed thatMYCNDK/Rb pathway during BL1521 treatment [12,24].
K. Ouwehand et al. / FEBS Letters 579 (2005) 1523–1528 1527ampliﬁed cells were more prone to apoptosis and showed a
more substantial decrease of p27, in comparison with MYCN
single copy cells, the induction of apoptosis, as a result of
BL1521 treatment is in line with the downregulation of p27.
The next possible contribution to the observed BL1521 in-
duced G1 arrest could be the altered presence of members of
the cyclin D–CDK4/6 complex. The cyclin D–CDK4 complex
is responsible for the hyperphosphorylation of under-
phosphorylated Rb. Under-phosphorylated Rb binds mem-
bers of the E2F family of transcription factor rendering them
inactive. Consequently, hyperphosphorylation of Rb results
in the release of the E2F transcription factors leading to the
expression of cyclin E and thus transition into the S phase of
the cell cycle (Fig. 6) [4,12,14,24]. In our experiments, we ob-
served a downregulation of CDK4 protein in response to
BL1521. Accordingly, we observed that the concentration of
hypophosphorylated form of the Rb protein increased, sug-
gesting that the downregulation of CDK4 may also be partly
responsible for the observed G1 phase arrest in response to
BL1521.
The third possible factor that could contribute to the induc-
tion of G1 phase arrest in response to BL1521 incubation is the
upregulation of the INK4 family members. Under particular
conditions HDACi have been reported to be able to upregulate
p15INK4b and p19INK4d expression [25,26]. The p15INK4b and
p19INK4d proteins function through the inhibition of the activ-
ity of the cyclin D–CDK4/6 complex [12,14,25,26]. However,
we could not detect any p19INK4d or p15INK4b, which might
be explained by the high incidence of deletion of the p15INK4b
locus, 9p21, and loss of heterozygozity of 9p in neuroblastoma
that have been reported, resulting in loss of expression [27,28].
A fourth possible factor that should be taken into consider-
ation is the eﬀect of MYCN on the activation of the cyclin D–
CDK4/6 complexes and on the downregulation of members of
the INK4 and CIP/KIP family. These eﬀects of MYCN en-
hance S phase progression and partly explain the high prolifer-
ative activity of MYCN ampliﬁed neuroblastoma cells [29,30].
Our previous results showed that MYCN expression had been
downregulated in response to BL1521, possibly contributing to
the induction of the G1 arrest [9]. However, Fig. 2 shows that
the G1 phase arrest, induced by BL1521 in both the MYCN
ampliﬁed and the MYCN single copy neuroblastoma cells,
takes place in an approximately similar fashion. This suggests
that the expression of MYCN, is not a major factor in estab-
lishment the G1 phase arrest.
Apart from the ability to induce cell cycle arrest, HDACi are
known to be able to induce apoptosis [9,31]. Previously, we
showed that BL1521 is able to induce PARP cleavage, an
end stage marker of apoptosis, in a panel of neuroblastoma
cell lines [9]. Our results showed that MYCN ampliﬁed cell
lines appear to be more sensitive to the induction of apoptosis
by BL1521 than the MYCN single copy cell lines. We have al-
ready discussed the possible role of p27 in this diﬀerence in
sensibility. Moreover, apart from the proliferative action of
MYCN, it also has a function in promoting apoptosis suggest-
ing a second reason for the diﬀerence in sensitivity towards
undergoing apoptosis [32]. A third optional mechanism for
the induction of apoptosis in response to BL1521 could be
the increased ratio between pro-apoptotic and anti-apoptotic
genes [33]. Currently, eﬀorts are being made to elucidate the
mechanism of apoptosis in neuroblastoma cells in response
to BL1521 treatment.In conclusion, these results show that the decrease in prolif-
eration observed in neuroblastoma cells in response to BL1521
treatment is a concerted result of the induction of apoptosis
and the induction of G1 phase arrest executed via the upregu-
lation of p21WAF1/CIP1 and or downregulation of CDK4.
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